Sound Blade Medical – a medical device company developing handheld ultrasound-guided histotripsy technology – announced the closing of an oversubscribed $16.5 million Series A funding round. And Amzak Health and Lumira Ventures co-led the round, with participation from Invest Nova Scotia.
The funds will be used to accelerate the development and clinical validation of its pioneering technology designed to bring the benefits of precision ultrasound therapy to a wide range of patient conditions.
Histotripsy is a non-invasive, non-ionizing, and non-thermal ablation technology guided by real-time imaging that utilizes focused ultrasound delivered from outside the body to destroy targeted tissue mechanically. And it works by inducing cavitation bubbles in the tissue at the ultrasound beam focus, using short, high-pressure pulses.
When the bubbles collapse, only liquified tissue remains. Because of the non-thermal nature of the technology, it may enable better immune and healing responses and avoid dangers associated with heating. In comparison to open surgery, histotripsy provides the possibility of dramatically improved patient outcomes, including less blood loss, fewer complications, reduced recovery time, and decreased chance of infection.
KEY QUOTES:
“We’re thrilled to have the support of such forward-thinking investors who share our vision for the future of Sound Blade and our technology. This funding enables us to rapidly advance our technology, expand our team and accelerate regulatory approvals to quickly bring our therapy to patients in need.”
- Jeremy Brown, Ph.D., Co-founder and CEO of Sound Blade
“Sound Blade’s handheld histotripsy has truly disruptive potential. We’re combining a highly accomplished founding team with an investor syndicate that has built many successful Medtech companies to unlock the full promise of this platform.”
- Tony Natale, MD, Partner at Amzak Health
“We’re excited to continue our long history of backing world-class medical device companies in Canada. With its roots at Dalhousie University and Nova Scotia Health, Sound Blade represents Lumira’s second investment in the exciting field of histotripsy for the non-invasive treatment of important diseases.”
- Gerry Brunk, Managing Director at Lumira Ventures
